Literature DB >> 33622324

TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination.

Jia-Xin Chen1, Da Xu1, Jian-Wei Cao1, Li Zuo2, Zhi-Tao Han3, Yi-Jun Tian1, Chuan-Min Chu1, Wang Zhou4, Xiu-Wu Pan5, Xin-Gang Cui6.   

Abstract

BACKGROUND: Renal cell carcinoma (RCC) is one of the most common malignant tumors originating from the renal parenchymal urinary epithelial system. Tripartite motif 47 (TRIM47) is a member of the TRIM family proteins, which has E3 ligase activity and has been demonstrated to be involved in the occurrence and prognosis of many tumors. The main purpose of this study is to explore the role and potential mechanism of TRIM47 in promoting malignant biological behavior of RCC.
MATERIALS AND METHODS: TRIM47 mRNA and protein levels in human renal cancer and paired normal adjacent tissues were detected by qRT-PCR and Western blot. The effects of TRIM47 knockdown and overexpression in renal cell carcinoma cells on cell proliferation, invasion and xenograft tumor growth in nude mice were analyzed. The molecular mechanism was explored by mass spectrometric exploration,Western blot and immunoprecipitation assays.
RESULTS: TRIM47 promoted RCC cell proliferation in vitro and in vivo as an oncogene. Mechanistically, TRIM47 exerted an E3 ligase activity by interacting with P53 protein to increase its ubiquitination and degradation, which further promoted the malignant biological behavior of RCC.
CONCLUSIONS: Our study demonstrated that the TRIM47-P53 axis played a functional role in RCC progression and suggested a potential therapeutic target for RCC.

Entities:  

Keywords:  E3 ubiquitin ligase; P53; Proliferation; Renal cell carcinoma; TRIM47

Year:  2021        PMID: 33622324     DOI: 10.1186/s12935-021-01831-0

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  42 in total

Review 1.  Current and future systemic treatments for renal cell carcinoma.

Authors:  Rosalie Fisher; Martin Gore; James Larkin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

2.  Kidney cancer: Characterizing late recurrence of renal cell carcinoma.

Authors:  Vincenzo Ficarra; Giacomo Novara
Journal:  Nat Rev Urol       Date:  2013-10-29       Impact factor: 14.432

Review 3.  Systemic Therapy for Metastatic Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Robert J Motzer
Journal:  N Engl J Med       Date:  2017-01-26       Impact factor: 91.245

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.

Authors:  Yan-Xiao Ji; Zan Huang; Xia Yang; Xiaozhan Wang; Ling-Ping Zhao; Pi-Xiao Wang; Xiao-Jing Zhang; Michele Alves-Bezerra; Lin Cai; Peng Zhang; Yue-Xin Lu; Lan Bai; Mao-Mao Gao; Huan Zhao; Song Tian; Yong Wang; Zhi-Xiang Huang; Xue-Yong Zhu; Yan Zhang; Jun Gong; Zhi-Gang She; Feng Li; David E Cohen; Hongliang Li
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

Review 6.  Integration of surgery and systemic therapy for renal cell carcinoma.

Authors:  Patrick A Kenney; Christopher G Wood
Journal:  Urol Clin North Am       Date:  2012-05       Impact factor: 2.241

7.  TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.

Authors:  Michaela U Gack; Young C Shin; Chul-Hyun Joo; Tomohiko Urano; Chengyu Liang; Lijun Sun; Osamu Takeuchi; Shizuo Akira; Zhijian Chen; Satoshi Inoue; Jae U Jung
Journal:  Nature       Date:  2007-04-19       Impact factor: 49.962

Review 8.  Treatment of renal cell carcinoma: Current status and future directions.

Authors:  Pedro C Barata; Brian I Rini
Journal:  CA Cancer J Clin       Date:  2017-09-29       Impact factor: 508.702

9.  Trim24 targets endogenous p53 for degradation.

Authors:  Kendra Allton; Abhinav K Jain; Hans-Martin Herz; Wen-Wei Tsai; Sung Yun Jung; Jun Qin; Andreas Bergmann; Randy L Johnson; Michelle Craig Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-25       Impact factor: 11.205

10.  The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3.

Authors:  Hui Song; Bingyu Liu; Wanwan Huai; Zhongxia Yu; Wenwen Wang; Jing Zhao; Lihui Han; Guosheng Jiang; Lining Zhang; Chengjiang Gao; Wei Zhao
Journal:  Nat Commun       Date:  2016-12-08       Impact factor: 14.919

View more
  8 in total

Review 1.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

2.  Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma.

Authors:  Weiyu Dai; Jing Wang; Zhi Wang; Yizhi Xiao; Jiaying Li; Linjie Hong; Miaomiao Pei; Jieming Zhang; Ping Yang; Xiaosheng Wu; Weimei Tang; Xiaoling Jiang; Ping Jiang; Li Xiang; Aimin Li; Jianjiao Lin; Side Liu; Jide Wang
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

3.  A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration.

Authors:  Di Zheng; Yunlong Zhang; Yuqi Xia; Fan Cheng
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

4.  Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Zhongbao Zhou; Zhenpeng Yang; Yuanshan Cui; Shuai Lu; Yongjin Huang; Xuanyan Che; Liqing Yang; Yong Zhang
Journal:  Front Genet       Date:  2022-03-08       Impact factor: 4.599

5.  TRIM47 is a novel endothelial activation factor that aggravates lipopolysaccharide-induced acute lung injury in mice via K63-linked ubiquitination of TRAF2.

Authors:  Yisong Qian; Ziwei Wang; Hongru Lin; Tianhua Lei; Zhou Zhou; Weilu Huang; Xuehan Wu; Li Zuo; Jie Wu; Yu Liu; Ling-Fang Wang; Xiao-Hui Guan; Ke-Yu Deng; Mingui Fu; Hong-Bo Xin
Journal:  Signal Transduct Target Ther       Date:  2022-05-06

Review 6.  Efp/TRIM25 and Its Related Protein, TRIM47, in Hormone-Dependent Cancers.

Authors:  Kotaro Azuma; Satoshi Inoue
Journal:  Cells       Date:  2022-08-08       Impact factor: 7.666

7.  Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma.

Authors:  Jun Cao; Bingbing Su; Rui Peng; Hao Tang; Daoyuan Tu; Yuhong Tang; Jie Zhou; Guoqing Jiang; Shengjie Jin; Qian Wang; Aoqing Wang; Renjie Liu; Qiangwei Deng; Chi Zhang; Dousheng Bai
Journal:  J Gastrointest Oncol       Date:  2022-08

Review 8.  The roles and targeting options of TRIM family proteins in tumor.

Authors:  Yuxin Zhang; Wenzhou Zhang; Lufeng Zheng; Qianqian Guo
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.